These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2685216)

  • 1. [Immunohistology of tumor tissue in local administration of recombinant interleukin-2 in head and neck cancer].
    Saito T; Kawaguti T; Yoda J; Kimura T; Tabata T
    Nihon Jibiinkoka Gakkai Kaiho; 1989 Aug; 92(8):1271-6. PubMed ID: 2685216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental study of local immunochemotherapy of head and neck cancer].
    Saito T
    Nihon Jibiinkoka Gakkai Kaiho; 1991 Dec; 94(12):1898-912. PubMed ID: 1779275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
    Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
    Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of local administration of RIL-2 in head and neck cancer].
    Saito T; Kakiuti H; Kuki K; Yokota M; Jinnin T; Kimura T; Fujiwara K; Yoda J; Kunimoto M; Arai H
    Nihon Jibiinkoka Gakkai Kaiho; 1989 Aug; 92(8):1265-70. PubMed ID: 2585201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An immunohistochemical study with monoclonal antibodies on lymphocytes infiltrating in cervical cancer].
    Okamoto Y; Sano T; Okamura S; Ueki M; Sugimoto O
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jun; 39(6):925-32. PubMed ID: 3302069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice].
    Hashimoto J
    Nihon Jibiinkoka Gakkai Kaiho; 1994 Jul; 97(7):1235-49. PubMed ID: 8064508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subset analysis of tumor infiltrating lymphocytes and peripheral blood lymphocytes in malignant glioma patients].
    Matsuhisa T
    No To Shinkei; 1995 May; 47(5):466-73. PubMed ID: 7786623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local administration trials of interleukin-2 for head and neck cancer.
    Saito T; Yoda J; Tabata T
    Auris Nasus Larynx; 1991; 18(2):169-78. PubMed ID: 1741710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    Itoh K; Tilden AB; Kumagai K; Balch CM
    J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection].
    Hosokawa T
    Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltrating leukocyte populations and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. A pathologic and immunophenotypic study.
    Valente G; De Stefani A; Jemma C; Giovarelli M; Geuna M; Cortesina G; Forni G; Palestro G
    Mod Pathol; 1990 Nov; 3(6):702-8. PubMed ID: 2263594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of tumor-infiltrating lymphocyte in primary malignant lymphoma of the central nervous system using double immunofluorescence staining method].
    Kunishio K; Matsuhisa T; Maeshiro T; Tsuno K; Shigematsu H; Mishima N; Matsumoto K; Furuta T; Ohmoto T; Nishimoto A
    No To Shinkei; 1992 Feb; 44(2):125-30. PubMed ID: 1533133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
    J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.